Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

Inclusion Criteria: * Prosthetic knee or hip joint infection * Infected joint spacer * Able to swallow tablets * Able to voluntarily sign the informed consent form * Females of childbearing potential must use an acceptable method of birth control * The joint infection must be attributed to bacterial pathogens sensitive to fusidic acid and rifampin Exclusion Criteria: * History of hypersensitivity or intolerability to sodium fusidate (Fucidin®), or to rifampin * Females who are pregnant or lactating * Requirement for significant immunosuppression * Bacteremia * Known cirrhosis or decompensated liver disease * Current treatment for HIV or Hepatitis C * Seizure disorder, requiring anti-convulsants